Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Argenx Se (ARGX) has released an update. Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval ...

Zai Lab Limited (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

November 11, 2024--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) ...

According to Benzinga Pro, argenx's peer group average for short interest as a percentage of float is 5.19%, which means the company has less short interest than most of its peers. Did you know that ...

argenx SE (NASDAQ:ARGX – Free Report) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) ...

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.